Riso Pharma Tech is a Canadian-based specialty pharmaceutical company focused on in-licensing late-stage and approved molecules for marketing and sales in Canada, certain European Union countries, Latin America, and the Middle East.
From large multi-national pharmaceutical companies to small biotechs, Riso's license deals have yielded successful product launches in its territories. Five regional offices and over 360 employees worldwide enable Riso to extend the reach of our partner companies' products.
With an extensive track record of greater than 10+ years marketing and sales success in its territories, and thanks to Riso's financial strength, Riso is aggressively pursuing new in-licensing opportunities across several therapeutic areas: oncology, supportive care, neurology, endocrinology and women's health.
